Search research articles
Contact Us
Filters
Showing results (61-70 of 107) with videos related to
Page
of 11
Sort By:
Haematologica
|
August 28, 2025
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study
Thomas Chalopin, Cyrille Hulin, Bruno Royer, et al.
British Journal of Haematology
|
March 12, 2026
Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia
Boris Sorin, Billal Azzouguen, Valentine Loustau, et al.
American Journal of Hematology
|
March 13, 2019
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study
Brigitte Pegourie, Lionel Karlin, Lotfi Benboubker, et al.
Blood Advances
|
January 28, 2025
Efficacy and safety of dapsone in adult primary immune thrombocytopenia
Marion Larue, Guillaume Moulis, Manuela Rueter, et al.
JAMA
|
December 7, 2017
Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial
Frank Bridoux, Pierre-Louis Carron, Brigitte Pegourie, et al.
Blood
|
August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Clinical Hematology International
|
July 25, 2024
The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge
Olivier Decaux, Ronan Garlantézec, Karim Belhadj-Merzoug, et al.
Blood
|
November 4, 2009
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
Murielle Roussel, Philippe Moreau, Anne Huynh, et al.
Clinical Hematology International
|
September 22, 2025
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study
Titouan Cazaubiel, Olivier Decaux, Bruno Royer, et al.
American Journal of Hematology
|
January 22, 2013
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients
Bruno Royer, Lavinia Merlusca, Julie Abraham, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 107) with videos related to
Sort By:
Page
of 11
Haematologica
|
August 28, 2025
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study
Thomas Chalopin, Cyrille Hulin, Bruno Royer, et al.
British Journal of Haematology
|
March 12, 2026
Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia
Boris Sorin, Billal Azzouguen, Valentine Loustau, et al.
American Journal of Hematology
|
March 13, 2019
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study
Brigitte Pegourie, Lionel Karlin, Lotfi Benboubker, et al.
Blood Advances
|
January 28, 2025
Efficacy and safety of dapsone in adult primary immune thrombocytopenia
Marion Larue, Guillaume Moulis, Manuela Rueter, et al.
JAMA
|
December 7, 2017
Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial
Frank Bridoux, Pierre-Louis Carron, Brigitte Pegourie, et al.
Blood
|
August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Clinical Hematology International
|
July 25, 2024
The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge
Olivier Decaux, Ronan Garlantézec, Karim Belhadj-Merzoug, et al.
Blood
|
November 4, 2009
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
Murielle Roussel, Philippe Moreau, Anne Huynh, et al.
Clinical Hematology International
|
September 22, 2025
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study
Titouan Cazaubiel, Olivier Decaux, Bruno Royer, et al.
American Journal of Hematology
|
January 22, 2013
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients
Bruno Royer, Lavinia Merlusca, Julie Abraham, et al.
Page
of 11